741 related articles for article (PubMed ID: 11692542)
1. [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].
Lopez M
Clin Ter; 2001; 152(3):203-6. PubMed ID: 11692542
[No Abstract] [Full Text] [Related]
2. Greater curability in advanced Hodgkin's disease?
Portlock CS
Cancer J Sci Am; 1999; 5(5):264-5. PubMed ID: 10526665
[No Abstract] [Full Text] [Related]
3. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
4. Pediatric Hodgkin's disease.
Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
6. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?
Andrieu JM; Colonna P
J Clin Oncol; 1998 Jun; 16(6):2283. PubMed ID: 9626234
[No Abstract] [Full Text] [Related]
7. [Hodgkin's disease and AIDS. Presentation of 5 cases].
García Alfonso P; Flores Sañudo E; Carrión Galindo R; Jara Sánchez C; Cosín Ochaita J
Rev Clin Esp; 1988 Apr; 182(6):314-6. PubMed ID: 2457232
[No Abstract] [Full Text] [Related]
8. Third-line salvage chemotherapy in Hodgkin's disease.
Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
10. Hodgkin's lymphoma--the great teacher.
Connors JM
N Engl J Med; 2011 Jul; 365(3):264-5. PubMed ID: 21774715
[No Abstract] [Full Text] [Related]
11. [The practice of chemotherapy with the DeVita protocol].
Gassmann W; Schmitz N; Löffler H
Dtsch Med Wochenschr; 1982 Jul; 107(27):1063-9. PubMed ID: 6177488
[No Abstract] [Full Text] [Related]
12. ABVD treatment of MOPP failures in Hodgkin's disease: a re-examination of goals of salvage therapy.
Clamon GH; Corder MP
Cancer Treat Rep; 1978 Mar; 62(3):363-7. PubMed ID: 77188
[No Abstract] [Full Text] [Related]
13. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
14. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease.
Bonadonna G; Zucali R; De Lena M; Valagussa P
Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270
[No Abstract] [Full Text] [Related]
15. Drug selection in the treatment of Hodgkin's disease.
Bonadonna G; Santoro A
Hematol Oncol; 1983; 1(1):3-12. PubMed ID: 6203820
[No Abstract] [Full Text] [Related]
16. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
17. Optimal treatment of early-stage Hodgkin disease.
Sullivan JW; Cooper JS
Radiology; 1993 Feb; 186(2):312-3. PubMed ID: 7678466
[No Abstract] [Full Text] [Related]
18. [Cancer of the testis after Hodgkin's disease. Apropos of 2 cases].
Robert M; Averous M; Lavabre-Bertrand T; Iborra F; Chevallier P; Rebillard X; Guiter J; Grasset D
J Urol (Paris); 1992; 98(3):178-80. PubMed ID: 1282922
[TBL] [Abstract][Full Text] [Related]
19. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
